71 related articles for article (PubMed ID: 17275249)
1. Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.
Thornton J; Ashcroft DM; Mughal MZ; Elliott RA; O'Neill TW; Symmons D
Arch Dis Child; 2006 Sep; 91(9):753-61. PubMed ID: 16690698
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological options in the treatment of osteogenesis imperfecta: A comprehensive review of clinical and potential alternatives.
Muñoz-Garcia J; Heymann D; Giurgea I; Legendre M; Amselem S; Castañeda B; Lézot F; William Vargas-Franco J
Biochem Pharmacol; 2023 Jul; 213():115584. PubMed ID: 37148979
[TBL] [Abstract][Full Text] [Related]
3. The influence of ibandronate treatment on bone density and biochemical bone markers in patients with osteogenesis imperfecta.
Ipach I; Kluba T; Wolf P; Pontz B; Mittag F
Orthop Rev (Pavia); 2012 Sep; 4(3):e29. PubMed ID: 23066497
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Bisphosphonate for Urolithiasis Complicated by Osteogenesis Imperfecta.
Deguchi R; Kohjimoto Y; Maruyama Y; Iwahashi Y; Muraoka S; Wakamiya T; Yamashita S; Hara I
Intern Med; 2024 Feb; 63(3):439-442. PubMed ID: 37344433
[TBL] [Abstract][Full Text] [Related]
5. Vertebral fracture assessment (VFA) for monitoring vertebral reshaping in children and adolescents with osteogenesis imperfecta treated with intravenous neridronate.
Diacinti D; Pisani D; Cipriani C; Celli M; Zambrano A; Diacinti D; Kripa E; Iannacone A; Colangelo L; Nieddu L; Pepe J; Minisola S
Bone; 2021 Feb; 143():115608. PubMed ID: 32829035
[TBL] [Abstract][Full Text] [Related]
6. Isolated olecranon fractures in children affected by osteogenesis imperfecta type I treated with single screw or tension band wiring system: Outcomes and pitfalls in relation to bone mineral density.
Persiani P; Ranaldi FM; Graci J; De Cristo C; Zambrano A; D'Eufemia P; Martini L; Villani C
Medicine (Baltimore); 2017 May; 96(20):e6766. PubMed ID: 28514292
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of osteogenesis imperfecta with bisphosphonates].
Tau C
Medicina (B Aires); 2007; 67(4):389-95. PubMed ID: 17891938
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?
Rauch F; Glorieux FH
Ann Med; 2005; 37(4):295-302. PubMed ID: 16019729
[TBL] [Abstract][Full Text] [Related]
9. Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate.
D'Eufemia P; Finocchiaro R; Celli M; Raccio I; Zambrano A; Tetti M; Smacchia P; Iacobini M
Biomed Pharmacother; 2010 Apr; 64(4):271-4. PubMed ID: 20359847
[TBL] [Abstract][Full Text] [Related]
10. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
[TBL] [Abstract][Full Text] [Related]
11. Intravenous neridronate in adults with osteogenesis imperfecta.
Adami S; Gatti D; Colapietro F; Fracassi E; Braga V; Rossini M; Tatò L
J Bone Miner Res; 2003 Jan; 18(1):126-30. PubMed ID: 12510813
[TBL] [Abstract][Full Text] [Related]
12. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
13. High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment.
D'Eufemia P; Finocchiaro R; Celli M; Zambrano A; Tetti M; Villani C; Persiani P; Mari E; Zicari A
Pediatr Res; 2008 Feb; 63(2):203-6. PubMed ID: 18091347
[TBL] [Abstract][Full Text] [Related]
14. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
